Business
kneat.com, inc. to complete non-brokered private placement
kneat.com, inc. to complete non-brokered private placement Canada NewsWire HALIF...
About this update from Kneat.com, Inc.
[{"type":"text","content":"\n\n\n\nkneat.com, inc. to complete non-brokered private placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nHALIFAX, May 10, 2017\n\n\n\nHALIFAX, May 10, 2017 /CNW/ - kneat.com, inc. (TSXV: KSI) (\"Kneat\" or the \"Company\"), the developer of the next generation Kneat.Gx platform for regulated industries, is pleased to announce that it intends to complete a non-brokered private placement for an estimated aggregate gross proceeds of $3,000,000 (the \"Offering\"). The Company intends to issue an estimated 5,000,000 common shares at an issue price of $0.60 per share.\n\nThe gross proceeds of the Offering will be used to accelerate development of the Kneat.Gx platform, increase the awareness of the platform in several regulated industries and enhance the team needed to support a growing list of customers.\n\n\"Our customers continue to see significant efficiencies and cost savings from the use of our platform.  We intend to capitalize on this momentum with both our on-premise and SaaS models and further penetrate the life sciences industry.\" said Eddie Ryan, Chief Executive Officer of Kneat.  \n\nClosing of the Offering is subject to the approval of the TSX Venture Exchange. All securities issued pursuant to the Offering will be subject to a statutory four-month hold period in accordance with Canadian securities legislation.\n\nAbout Kneat\n\nKneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat.Gx software platform.  Kneat.Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management.  Kneat.Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11 compliant platform.  Users with correct permissions can see everything in real time.  Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.\n\nCautionary and Forw...